BRCA2 and cancer: Our results corroborate those of another recent population-based application of WES linked to health records10 to evaluate cancer risk in individuals with pathogenic variants in BRCA1 or BRCA2, demonstrating the value of WES to identify high-penetrance rare alleles that are associated with clinical phenotypes; such efforts can be applied across other genetic disorders, enabling the implementation of precision medicine at the population level.